Table 5 Subgroup analysis of hematological toxicity

Median age (years)

< 45

rate^a

82% (42–100%)

P > 0.05

74% (44–95%)

P > 0.05

79% (4–100%)

P > 0.05

N^b

146

156

65

≥45 and < 60

rate

82% (64–96%)

57% (39–75%)

77% (59–92%)

N

565

605

580

> 60

rate

72% (56–85%)

50% (28–71%)

53% (39–68%)

N

428

443

443

Pathological type

leukemia

rate

62% (17–98%)

P > 0.05

60% (22–93%)

P > 0.05

69% (17–100%)

P > 0.05

N

244

254

176

lymphoma

rate

83% (73–90%)

60% (46–73%)

68% (54–80%)

N

737

742

721

MM

rate

88% (64–100%)

57% (36–77%)

53% (21–84%)

N

132

182

136

Targeting antigen

CD19

rate

73% (58–86%)

P = 0.0001

56% (40–71%)

P > 0.05

64% (48–79%)

P > 0.05

N

918

933

834

non-CD19

rate

93% (84–99%)

70% (54–83%)

74% (46–95%)

N

278

328

282

Proportion of previous HSCT

< 50%

rate

80% (56–97%)

P > 0.05

74% (58–87%)

P > 0.05

74% (58–87%)

P > 0.05

N

978

1071

973

≥50%

rate

77% (62–89%)

52% (34–69%)

49% (23–74%)

N

94

94

94

Median lines of prior therapy

< 4

rate

79% (61–93%)

P > 0.05

42% (27–58%)

P = 0.0252

55% (43–67%)

P > 0.05

N

673

707

690

≥4

rate

81% (69–92%)

67% (53–80%)

65% (43–84%)

N

267

288

238

Co-stimulatory molecule

CD28

rate

88% (82–93%)

P > 0.05

79% (59–94%)

P = 0.0054

79% (64–92%)

P = 0.0274

N

207

207

207

41BB

rate

65% (41–86%)

36% (17–57%)

55% (42–67%)

N

463

453

453

Median age in leukemia cases

< 20

rate

61% (10–100%)

P > 0.05

45% (14–79%)

P = 0.032

N

60

60

≥20

rate

83% (38–100%)

87% (66–99%)

N

94

104

Median age in lymphoma cases

< 60

rate

85% (63–99%)

P > 0.05

59% (35–81%)

P > 0.05

80% (64–93%)

P = 0.0424

N

404

394

394

≥60

rate

67% (51–81%)

47% (23–72%)

52% (34–69%)

N

395

410

410

Median age (years)

< 45

rate

57% (28–84%)

P > 0.05

33% (20–47%)

P > 0.05

38% (22–56%)

P > 0.05

N

314

374

261

≥45 and < 60

rate

59% (40–76%)

32% (22–43%)

34% (22–46%)

N

592

662

645

> 60

rate

59% (45–71%)

32% (23–43%)

28% (18–40%)

N

531

514

546

Pathological type

leukemia

rate

48% (22–76%)

P > 0.05

28% (16–42%)

P > 0.05

41% (28–54%)

P > 0.05

N

390

450

350

lymphoma

rate

60% (49–71%)

32% (25–40%)

24% (16–34%)

N

985

825

979

MM

rate

58% (29–84%)

40% (28–53%)

31% (15–50%)

N

215

261

350

Targeting antigen

CD19

rate

52% (40–64%)

P = 0.0088

29% (22–36%)

P > 0.05

28% (21–35%)

P > 0.05

N

1313

1221

1267

non-CD19

rate

75% (57–90%)

43% (32–54%)

42% (24–62%)

N

339

398

371

Proportion of previous HSCT

< 50%

rate

58% (44–71%)

P > 0.05

33% (26–41%)

P > 0.05

36% (26–45%)

P > 0.05

N

1093

1180

1146

≥50%

rate

59% (34–82%)

30% (16–46%)

34% (19–50%)

N

258

239

183

Median lines of prior therapy

< 4

rate

53% (38–68%)

P > 0.05

28% (20–36%)

P > 0.05

32% (25–39%)

P > 0.05

N

961

924

999

≥4

rate

60% (46–73%)

34% (24–43%)

24% (13–36%)

N

419

440

390

Co-stimulatory molecule

CD28

rate

47% (34–66%)

P > 0.05

47% (34–60%)

P = 0.0004

29% (18–41%)

P > 0.05

N

405

238

405

41BB

rate

53% (38–74%)

18% (10–27%)

22% (11–34%)

N

471

463

471

Median age in leukemia cases

< 20

rate

46% (18–75%)

P > 0.05

23% (10–40%)

P > 0.05

36% (18–70%)

P > 0.05

N

186

178

65

≥20

rate

58% (11–97%)

37% (20–56%)

42% (28–65%)

N

114

182

174

Median age in lymphoma cases

< 60

rate

64% (45–82%)

P > 0.05

32% (22–44%)

P > 0.05

31% (19–43%)

P > 0.05

N

485

477

485

≥60

rate

49% (32–67%)

27% (16–40%)

22% (12–34%)

N

562

410

577

Median age in MM cases

< 60

rate

34% (14–57%)

P = 0.0227

29% (16–44%)

P = 0.0356

26% (9–48%)

P > 0.05

N

58

136

119

≥60

rate

73% (47–93%)

48% (37–58%)

48% (18–79%)

N

95

84

95